An interventional study of Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery and Spontaneous recovery in Mivacurium, Neostigmine and Residual Paralysis, sponsored by Université Libre de Bruxelles. Completed at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-19.
Sponsored by Université Libre de Bruxelles · Not applicable, Interventional, and Other
The antagonism of neuromuscular blocking agents (NMBA) (or curares), as well as the antagonism of other drugs used in anesthesia, is a major challenge for the speciality.
Residual paralysis is indeed a risk factor for post-operative morbidity and mortality and antagonization of curares at the end of the procedure is associated with a reduction in mortality .
Its use should be as large as possible and its contraindications are extremely rare.
The antagonism of the NMBA reduces the duration of the neuromuscular block and the complications that are associated .
In this study, the investigators use mivacurium (or Mivacron) as non-depolarizing curare and neostigmine as an antagonist.
Neostigmine reduces the duration of the neuromuscular block induced by mivacurium, By reducing the breakdown of acetylcholine, neostigmine induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
But the use of neostigmine in current practice is not very widespread in this clinical situation.
The reduction in the duration of the block is significant in comparison with a spontaneous recovery .
Moreover, spontaneous recovery is not always complete and sometimes very long.
Nevertheless, its action is effective and this study could support this use but also specify the duration and the quality of the return to normal of the neuromuscular transmission.
750 studies on the registry are indexed under Paralysis; 133 are open to participants now.
This study's enrollment of 80 is above the median of 30 across 537 interventional studies indexed under Paralysis.
Browse Paralysis studies →Université Libre de Bruxelles is the lead sponsor of 44 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
Drug: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery
A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
Drug: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery
A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
Drug: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery
A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
Drug: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery
A control group : not receiving an antagonist (spontaneous recovery)
Other: Spontaneous recovery
just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
Change in TOF ( Train Of Four) measure
Time frame: for each patient, measure of Train Of Four at 3, 6, 9, 12, 15 minutes
Plan to share: Yes
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université Libre de Bruxelles